Oxfordshire's Xerion Healthcare awarded Innovate UK SMART Grant

By Sam Pither

4 November 2022

Share

The Business Magazine article image for: Oxfordshire's Xerion Healthcare awarded Innovate UK SMART Grant

Xerion Healthcare, a University of Oxford spin-out working on an innovative treatment for brain tumours, has been awarded an Innovate UK SMART Grant alongside Medicines Discovery Catapult (MDC).

Currently, a person diagnosed with a brain tumour will undergo surgery to remove as much of it as possible, followed by radiotherapy and chemotherapy. Unfortunately, tumours will often return after removal, regularly with rapid regrowth.

However, the extensive medical intervention needed (usually in the form of radiotherapy, which improves treatment outcomes but has a detrimental effect on healthy tissue) when this happens does not often translate into a significant increase in survival rate yet negatively impacts the patient’s quality of life.

Oxfordshire SME Xerion has developed a nanoparticle solution which increases the effectiveness of radiotherapy, but without damage to health tissue around the tumour.

Using the grant from Innovate UK, Xerion will work alongside MDC, which has developed a clinically relevant model of a tumour which the radiotherapy-enhancing nanoparticles will be released into. The two companies will then track tumour regrowth both with and without the particles to determine efficacy.

This will be carried out using MDC's pre-clinical radiotherapy platform and advanced imaging capability.

The data generated in these tests will then form the basis of a submission to the Medicines and Healthcare Products Regulatory Agency (MHRA), moving Xerion’s novel approach closer to clinical trials and, subsequently, patients.

Dr Gareth Wakefield, Chief Technology Officer at Xerion Healthcare, said: “High-grade brain tumours are an extremely challenging disease type with little improvement in outcomes over the last forty years.

“New treatment options are urgently needed to reduce the almost inevitable regrowth of these tumours following resection. To develop these treatments, advanced models and imaging are required.

“By partnering with the experts at MDC, Xerion will be able to apply its nanoparticle radiotherapy enhancing technology to a realistic model of this disease, bringing novel treatments closer to the clinic.”

Dr Martin Main, Chief Scientist at Medicines Discovery Catapult, said: "At MDC, we are driven by reshaping drug discovery for the benefit of patients, and this project is the epitome of that.

“Tragically, brain tumours kill more people under 40 than any other type of cancer, so there is an urgent need for new therapeutic approaches to treat this disease.

“Combining Xerion's radiotherapy expertise with MDC's advanced imaging capability will allow us to address a critical unmet need for treating aggressive brain tumours and move one step closer to improving the quality of life for many patients."

By Sam Pither

Sam is the Regional Editor of Biz News, responsible for both Hampshire and Dorset.

A new recruit to journalism, Sam started writing for the Business Magazine as a freelancer in May of 2022 after completing his degree in English at University College London. His passion for local businesses and ability to tell a story soon caught the attention of the publication’s management team and have led to his meteoric rise.

Sam, who lives in central Reading, takes a particular interest in technology, gaming and food and drink, having been a chef before starting his degree.